The Critical Imperative of Global HCP Sanction Data in Life Sciences Engagements

Interactions between life sciences organizations and healthcare professionals (HCPs), from clinical investigators to promotional speakers, form the operational backbone of the industry. However, this ecosystem operates under strict regulatory oversight. HCP sanction and exclusion data is the key asset determining whether an engagement is a strategic success or a major compliance violation.

Failing to continuously monitor HCP status exposes pharmaceutical and medical device manufacturers to financial penalties, rejected clinical data, and severe reputational damage. Global regulators enforce strict standards where ignorance offers no legal defense: if an organization could have discovered an exclusion through routine screening, it is held fully liable.

Compounding Liability Across Transatlantic Watch-lists

Engaging a sanctioned HCP triggers compounding exposure across both US and European regulatory frameworks.

• US Enforcement: The HHS Office of Inspector General (OIG) maintains the List of Excluded Individuals/Entities (LEIE), which imposes an absolute payment prohibition on federal healthcare reimbursements. Additionally, CMS maintains a Preclusion List for Medicare Advantage and Part D, requiring dual monitoring.

• EU Enforcement: In Europe, compliance teams must cross-reference the EU Consolidated Financial Sanctions List—maintained by the European Commission and the Council of the EU—alongside national member-state registries to prevent illegal payments or partnerships with restricted individuals.

  
  

Retaining improper payments creates significant financial risk. Under US law, failing to repay over-payments can trigger treble damages under the False Claims Act (FCA). In 2025 alone, over 35 healthcare organizations paid $26+ million in Civil Monetary Penalties (CMPs) and settlements for exclusion violations.

Liability Category	Governing Authority	Enforcement Standard & Maximum Penalties
General Exclusion Violation	OIG (42 CFR § 1003.200)	Up to $24,947 per violation across direct/indirect care
Medicare Advantage / Part D	OIG (42 CFR § 1003.410)	Up to $47,596 per contracting violation
False Claims Act Liability	DOJ / FCA	Treble (3x) damages plus per-claim penalties
EU Sanctions Non-Compliance	EU Member States / Council	Fines, asset freezes, and operational license revocation
FDA Debarment Violation	FDA (FD&C Act)	Up to $250,000 in fines for contracting debarred parties

Organizations identifying internal violations can use the OIG’s Self-Disclosure Protocol (SDP) to cap damages at a 1.5x multiplier, provided pre-disclosure screening was thorough.

Trial Integrity and Executive Accountability

• Clinical Trial Integrity: The FDA’s Bioresearch Monitoring (BIMO) program targets protocol non-compliance and data falsification. Disqualified investigators are placed on the FDA Debarment List. If a sponsor utilizes a debarred investigator, regulators can reject clinical data outright, halting drug approval and wasting years of research.

• Personal Executive Liability: Under the Park Doctrine (Responsible Corporate Officer doctrine), high-ranking executives face strict criminal liability for compliance failures, even without direct knowledge or intent. OIG can also ban executives personally from healthcare programs. Automated screening is an executive necessity.

  
  

Managing Anti-Kickback Risks in Screening Programs

Modernizing screening requires navigating Anti-Kickback Statute (AKS) risks. In OIG Advisory Opinion 25-04, regulators issued an unfavorable opinion on a medical device company paying a third-party vendor to screen health system customers. Because this absorbed costs hospitals would otherwise bear, it constituted prohibited "remuneration" under the AKS. Life sciences firms cannot structure third-party screening arrangements that relieve customers of their own operational costs.

Modernizing the HCP Engagement Lifecycle with Alanda

Manual checks, spreadsheets, and CRM add-ons create dangerous audit gaps. An HCP cleared during contracting might have their license revoked mid-engagement.

Leading platforms like Alanda’s Activity Management solution embed real-time, automated compliance into operational workflows:

1. Continuous "Do Not Engage" (DNE) Gatekeeping: Proactively screens HCPs against the LEIE, FDA Debarment list, GSA SAM, all 50 state Medicaid lists, and the EU Consolidated Financial Sanctions List. Sanctioned individuals are automatically blocked before contracts are signed.

2. Integration with FMV and Spend Limits: Synthesizes sanction data with Fair Market Value (FMV) tiering and aggregate spend limits (CAPS) to maintain compliance with federal Open Payments and state spending bans.

3. Enterprise Integration: Connects with SAP, Concur, Salesforce, and Veeva to maintain an automated, timestamped audit trail across global engagements.

Conclusion

Treating HCP sanction screening as a periodic administrative chore creates existential risk. By shifting from periodic checks to continuous, automated screening embedded in the engagement lifecycle, life sciences organizations can eliminate compliance threats at the point of origin and engage the global medical community with confidence.